News Archive
Dec 2020
Dec 22, 2020 VIRALEZE COVID-19 nasal spray study to commence in January
Dec 10, 2020 VIRALEZE™ COVID-19 nasal spray to be ready for market Q1CY21
Nov 2020
Nov 20, 2020 Starpharma Viraleze: COVID-19 Nasal Spray Development
Nov 20, 2020 AGM Chairman address and CEO presentation
Nov 19, 2020 SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray
Oct 2020
Oct 30, 2020 Quarterly Cashflow and Activities Report
Oct 29, 2020 Completion of Placement and SPP raises $48.9M in total
Oct 21, 2020 Starpharma (ASX:SPL) banks $5.7M government R&D tax refund
Oct 21, 2020 Starpharma receives $5.7M R&D tax incentive refund
Oct 20, 2020 Shareholder Update October 2020
Oct 16, 2020 Biotech In Focus In 2020
Oct 08, 2020 $2B R&D win for biotech, resources
Oct 08, 2020 Allianz ups Starpharma stake as M&G sells
Oct 07, 2020 Share Purchase Plan offer document
Sep 2020
Sep 30, 2020 Starpharma completes oversubscribed A$45M placement - SPP to follow
Sep 30, 2020 Investor Presentation
Sep 25, 2020 VivaGel® BV secures TGA approval for prevention of BV
Sep 17, 2020 Starpharma is interviewed by Stockhead to give a company overview and provide an update on its COVID-19 nasal spray
Sep 17, 2020 Starpharma to present at OTCQX Life Sciences Investor Forum
Sep 14, 2020 SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Sep 03, 2020 Starpharma awarded $1M MRFF funding for COVID-19 spray
Sep 01, 2020 SPL creates slow release soluble DEP® remdesivir nanoparticle
Aug 2020
Aug 27, 2020 Annual report and full year financial results
Aug 26, 2020 2GB’s Jim Wilson interviews Starpharma CEO Dr Jackie Fairley
Aug 26, 2020 ABC News features Starpharma on ‘The Kohler Report’
Aug 26, 2020 Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19
Aug 25, 2020 SPL7013 nasal spray for COVID-19 – development update
Aug 17, 2020 Starpharma signs new DEP® partnership with Chase Sun
Jul 2020
Jul 30, 2020 Quarterly Cashflow and Activities Report
Jul 30, 2020 DEP® docetaxel and gemcitabine combination trial commences
Jul 27, 2020 AZD0466 trial opens MD Anderson Cancer Center as a site
Jul 09, 2020 New Australian site opening for DEP® trials
Jul 03, 2020 The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products
Jul 03, 2020 Pandemic a catalyst for boosting commercial outcomes, says Starpharma CEO
Jun 2020
Jun 29, 2020 DEP irinotecan boosts immuno-oncology in colon cancer models
Jun 25, 2020 The 7.30 report interviews Starpharma CEO Dr Jackie Fairley
Jun 25, 2020 Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report
Jun 23, 2020 Multiple DEP® products showcased at AACR 2020
Jun 19, 2020 SBS speaks to Starpharma CEO Dr Jackie Fairley on female representation in business
Jun 19, 2020 Ausbiz interviews Starpharma CEO Dr Jackie Fairley
Jun 18, 2020 Starpharma to present at OTCQX Virtual Investor Conference
Jun 17, 2020 DEP® lutetium effective in human prostate cancer model
Jun 16, 2020 VivaGel® BV launched in central and eastern European countries
May 2020
May 18, 2020 Starpharma CEO Dr Jackie Fairley on Proactive Investors (Canada)
May 14, 2020 Shareholder Update May 2020
May 11, 2020 Starpharma CEO Dr Jackie Fairley on ausbiz
May 07, 2020 DEP® irinotecan phase 2 commences after positive phase 1 results
May 05, 2020 Starpharma presents at Macquarie Australia Conference
Apr 2020
Apr 22, 2020 Australia’s biotech sector tests multiple agents to fight COVID-19
Apr 16, 2020 Condom gel compound proves effective against COVID-19
Apr 16, 2020 Starpharma Reports Positive Results From SARS-CoV-2 Antiviral Testing Of SPL7013
Apr 16, 2020 Starpharma’s SPL7013 Shows Significant Activity Against SARS-CoV-2 (coronavirus)
Apr 15, 2020 SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)
Apr 07, 2020 Quarterly Cashflow and Activity Report
Mar 2020
Mar 30, 2020 COVID-19 measures
Mar 04, 2020 Okamoto licenses VivaGel® antiviral condom in Asian countries
Mar 02, 2020 Starpharma appoints David McIntyre and Appendix 3X
Feb 2020
Feb 24, 2020 Interim Report and Half-Year Financial Results
Feb 13, 2020 Starpharma collects milestone payment from AstraZeneca
Feb 13, 2020 Starpharma share price charges higher on product launch news
Feb 13, 2020 VivaGel BV launched in Asia
Feb 12, 2020 David McIntyre appointed as non-executive director
Feb 11, 2020 Starpharma receives US$3M milestone from AstraZeneca
Jan 2020
Jan 30, 2020 Shareholder Update January 2020
Jan 29, 2020 Quarterly Cashflow Report